Study for Safety and Efficacy of high dose (60-63GY) radiotherapy in the postoperative adjuvant treatment of low-grade glioma with IDH wild

Study for Safety and Efficacy of high dose (60-63GY) radiotherapy in the postoperative adjuvant treatment of low-grade glioma with IDH wild,a phase II non-randomized historical controlled study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800018576

Enrollment

Unknown

Registered

2018-09-25

Start date

2020-10-01

Completion date

Unknown

Last updated

2018-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low-grade glioma

Interventions

Case series:radiation dose 60-63GY

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-70 years old; 2. postoperative histologically confirmed low-grade glioma; 3. IDH wild by Molecular pathological detection; 4. ps=2

Exclusion criteria

Exclusion criteria: 1. Suffering from other malignant tumors; 2. No brain radiotherapy before; 3. Other circumstances that are not suitable for including.

Design outcomes

Primary

Measure	Time frame
progress-free survival and overall survival;	—

Secondary

Measure	Time frame
Quality of life and Nerve function;	—

Countries

China

Contacts

Public ContactYahua Zhong

Zhongnan Hospital of Wuhan University

doctorzyh73@163.com+86 027 67813154

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026